A blood-vessel signaling pathway that may cause harmful brain blood-flow drops after seizures and head injury
The Role of the Endothelial NPYR1-TRPC3-ET1 Signaling Axis in Neurovascular Coupling Dysfunction
This work looks at whether a specific blood-vessel signaling pathway causes dangerous drops in brain blood flow in people with seizures or traumatic brain injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-11285378 on NIH RePORTER |
What this research studies
From my perspective as a patient, the team is trying to find out why blood vessels in the brain sometimes tighten when neurons are overactive after seizures or head injury, cutting off needed oxygen and glucose. They use specially engineered mice that lack endothelial TRPC3 or NPYR1 and give drugs that block NPYR1, TRPC3, or endothelin-1 receptors to see how vessels respond. The researchers measure blood flow and vessel behavior during seizure-like activity to map the signaling steps that lead to the harmful "inverse hemodynamic response." Finding that chain of events could point to ways to stop the dangerous vasoconstriction.
Who could benefit from this research
Good fit: People with recent or recurrent seizures, recent traumatic brain injury, or other acquired brain injuries are the most relevant candidates for future trials based on this work.
Not a fit: People without seizure-related or neurovascular blood-flow problems, or whose symptoms come from unrelated causes, are unlikely to benefit from this specific pathway-focused work.
Why it matters
Potential benefit: If correct, this could identify drug targets to prevent harmful brain blood-flow drops and reduce damage after seizures or traumatic brain injury.
How similar studies have performed: Prior studies have linked endothelin and neurovascular coupling to blood-flow changes, but directly connecting the endothelial NPYR1-TRPC3-ET1 pathway is a novel approach not yet tested in humans.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Zheng, Fang — Univ of Arkansas for Med Scis
- Study coordinator: Zheng, Fang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.